Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Ítems similars

• Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
  per: Fisher, C, et al.
  Publicat: (1993)
• Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells
  per: Huan Wang, et al.
  Publicat: (2021-03-01)
• Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research
  per: Fa-Min Gong, et al.
  Publicat: (2024-01-01)
• Cardiorenal Syndromes and Sepsis
  per: C. Chelazzi, et al.
  Publicat: (2011-01-01)
• Sepsis: syndrome or disease?
  per: Ali Mohammad Sabzghabaee, et al.
  Publicat: (2010-07-01)